Phase II study of TAS-102 plus bevacizumab as maintenance therapy after induction chemotherapy with bevacizumab, oxaliplatin, and fluoropyrimidine in patients with metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
Interventions: TAS-102 plus Bevacizumab TAS-102 35 mg/time, twice a day, oral intake Day1-5,8-12 Bevacizumab venous injection, 5.0 mg/kg Day1,15 Patients will continue study treatment until disease progression Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized
创建时间：
2017-12-15
